Nektar Therapeutics (NKTR) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $75.92 --0%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
